$CRSP News

Crispr Therapeutics: A Catalyst-Rich 12 Months Ahead

HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target

Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target

Crispr Therapeutics: Casgevy's Pediatric Win A Trigger For Bullish Sentiment

CRISPR Therapeutics AG (CRSP) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transcript

CRISPR Therapeutics AG (CRSP) Presents at 46th Annual William Blair Growth Stock Conference Transcript

CRISPR Therapeutics AG (CRSP) Presents at Jefferies Global Healthcare Conference 2026 Transcript

Is CRISPR Therapeutics (CRSP) One Of The Under-The-Radar Stocks With Massive Upside For 2026?

CRISPR Therapeutics to Participate in Upcoming Investor Conferences

Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline Progress

CRISPR Therapeutics AG (CRSP) Reports Q1 2026 Results

CRISPR Therapeutics AG (CRSP) is Attracting Investor Attention: Here is What You Should Know

CRISPR Therapeutics Enters Second Phase As CASGEVY Uptake And Data Build

Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56

CRISPR Therapeutics AG (CRSP) Presents at Bank of America Global Healthcare Conference 2026 Transcript

1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist?

CRISPR Therapeutics AG (CRSP) Is a Trending Stock: Facts to Know Before Betting on It

Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82

Is It Time To Reconsider CRISPR Therapeutics (CRSP) After A 58% One Year Rally?

CRISPR Therapeutics to Present at the Bank of America Securities 2026 Global Healthcare Conference